close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Mind Medicine (MindMed) Inc. - Common Shares (NQ:MNMD)

15.02 UNCHANGED
Last Price Updated: 4:00 PM EST, Jan 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Mind Medicine (MindMed) Inc. - Common Shares

< Previous 1 2
...
22 23 24 25 26 27 28 29 Next >
News headline image
Steep Decline In Cannabis & Psychedelic Compounds-Based Drug Stocks Continues: DOWN -16.6% MTD ↗
All 12 constituents in the Marijuana & Psychedelic Compounds-Based Drug Stocks Index continue to decline. How do their performances compare month-to-date and YTD? 
Via Talk Markets
News headline image
MindMed Shares Update On Phase 2b Trials of LSD For Treating Generalized Anxiety Disorder ↗
MindMed (NASDAQ: MNMD) (NEO: MMED), a clinical-stage biotech company that is assembling a compelling drug development pipeline of innovative treatments based on psychedelic... 
Via Benzinga
News headline image
The Year In Review For Psychedelic Drug Stocks: 2021 ↗
2021 was two different 
Via Talk Markets
News headline image
MNMD Stock: The Latest Psychedelic Drug News MindMed Fans Should Watch ↗
MindMed's LSD trials are facing a regulatory roadblock but MNMD stock isn't being forced down. Here's why investors should watch. 
Via InvestorPlace
News headline image
Marijuana & Psychedelic Compounds-Based Drug Stocks Now Down -16% YTD ↗
A look at which index has done the best so far in December: the Marijuana Drug Stocks Index or the Psychedelic Compounds-Based Drug Stocks Index. 
Via Talk Markets
News headline image
MindMed Advances Phase 2a LSD Microdose Trial For Adult ADHD ↗
Neuro-pharmaceutical and psychedelics company Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) announced Friday the initiation of Phase 2a proof-of-concept trial of LSD (... 
Via Benzinga
News headline image
Mind Medicine to Study Effect of Time on LSD Microdosing ↗
Mind Medicine (NASDAQ: MNMD), a psychedelic medicine biotech company, plans to conduct research on how the time of the day during which an individual consumes microdoses of a... 
Via Benzinga
News headline image
Cannabis Movers & Shakers: HEXO, Agrify, MindMed, KetamineOne ↗
Agrify Taps Barry Turkanis To Its Board Of Directors Vertically integrated cannabis company Agrify Corporation (NASDAQ... 
Via Benzinga
News headline image
MindMed Names Robert Barrow As CEO & Director, Announces Management Shake-Ups ↗
Psychedelic-focused biotech company Mind Medicine Inc. (NASDAQ: 
Via Benzinga
News headline image
Trip to Sustainability? This Company Is Developing Synthetic Psychedelics To Attempt to Fight Mental Illness ↗
Photo by Raimond Klavins 
Via Benzinga
News headline image
Fintech Focus For December 13, 2021 ↗
One Big Thing In Fintech: Understanding the fundamentals of a publicly-listed company can help with making more informed investment decisions. Still, many fail in conducting any... 
Via Benzinga
News headline image
EXCLUSIVE: MindMed CEO Rob Barrow On Growth Aspirations, Development Pipeline ↗
This past summer, Mind Medicine (MindMed) Inc (NASDAQ: MNMD), a medicine biotech in the psychedelics sector, announced the departure of co-founder and CEO J.R. Rahn. In learning... 
Via Benzinga
News headline image
Psilera's DMT-Derived Drug Sees Positive Results in Pre-Clinical Study ↗
Psilera is a Florida-based biotechnology company focused on developing drugs to treat mental disorders using non-hallucinogenic derivatives from psychedelic compounds. The... 
Via Benzinga
Topics Derivatives
News headline image
FDA Shows Support For Development Of MindMed's Session Monitoring System ↗
Psychedelic-focused biotech company Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) recently met with the US Food and Drug Administration (FDA) Center for Devices and... 
Via Benzinga
News headline image
This Company Is Making Synthetic Psychedelics With a Goal To Combat Mental Illness ↗
Photo by Michael Longmire on... 
Via Benzinga
News headline image
MNMD Stock Pops Higher After MindMed Unveils ‘Psychedelic’ Data ↗
MNMD stock is up today after MindMed reported positive findings on the interactions between psilocybin and an antidepressant. 
Via InvestorPlace
News headline image
Antidepressants Can Be Used During Psilocybin Treatment, A New MindMed & Liechti Lab Study Finds ↗
Psychedelics-focused biotech company Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) announced the publication of its first data on the interaction of a selective... 
Via Benzinga
News headline image
Psychedelic Drug Stocks Continued To Decline Last Week ↗
The 12 constituents in our Pure-Play Psychedelic Compounds-Based Drug Stocks Index declined -5.7% last week; it's now -16.1% so far in November. 
Via Talk Markets
News headline image
3 Psychedelic Stocks for Potential Out-of-This-World Gains ↗
Psychedelic drugs could be a major game-changer when it comes to treating mental illness. All as psilocybin, LSD, and MDMA show progress. 
Via InvestorPlace
News headline image
MindMed Q3 Earnings: Big Improvement, Kicks Off Sleep & Cognitive Study With Dose Low-Dose LSD ↗
MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a biotech company developing psychedelic-inspired therapies, announced its financial results late Monday for the third quarter... 
Via Benzinga
News headline image
Cannabis Movers & Shakers: Mind Medicine, Avant Brands, Delic, Agrify, Ascend Wellness, Pure Beauty ↗
Mind Medicine Appoints Maria A. Oquendo To Scientific Advisory Board Psychedelic-focused biotech company Mind Medicine Inc. 
Via Benzinga
Topics Cannabis
News headline image
Compass Pathways Phase II Results: A Disappointment For Some, An Opportunity For Others ↗
Compass Pathways reported 
Via Talk Markets
News headline image
Behind the Wall: Psychedelics Have “Absolutely Transformational” Potential ↗
Is now the time to invest in psychedelic stocks? Dustin Robinson, founder of venture capital firm Iter Investments, says yes and explains why. 
Via InvestorPlace
News headline image
Compass Pathways Goes On Bad Trip, Despite 'Positive' Results From Psilocybin Trial ↗
Shares plunged, despite a psilocybin-based drug reducing depression in a trial. 
Via Investor's Business Daily
News headline image
Compass Pathways 2.0: A New Rally In Psychedelic Stocks? ↗
Compass Pathways' IPO sparked a sector-wide rally in 2020. Now CMPS is on the move again. Is history about to repeat? 
Via Talk Markets
Topics Initial Public Offering
News headline image
How This Company Is Using Psychedelic Medicines and Therapies to Treat Addiction and Mental Illness ↗
Courtesy of: MindMed The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored c... 
Via Benzinga
News headline image
Magic Mushrooms and Ecstasy: New Treatment For Autism Spectrum Disorders? ↗
Much like cannabis, psychedelics are catch... 
Via Benzinga
Topics Cannabis
News headline image
Psyched: MindMed's MDMA Program For Autism, Small Pharma's New Patent, NovaMentis' Orphan Drug Designation ↗
The Week In Psychedelics: 
Via Benzinga
Topics Intellectual Property
News headline image
Biotech Companies Are Embracing the Growing Psychedelic Drug Market To Confront a Global Increase in Depression and Anxiety ↗
Image by 3D Animation Production Company from Pixabay The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team... 
Via Benzinga
News headline image
Phase 2 Trial On Ayahuasca's Active Ingredient Puts Small Pharma On Track To Winning The Psychedelics Race ↗
Small Pharma Inc. (OTCQB:DMTTF) (TSXV: 
Via Benzinga
< Previous 1 2
...
22 23 24 25 26 27 28 29 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today